Benjamin Hanfstein

3.6k total citations · 1 hit paper
28 papers, 1.1k citations indexed

About

Benjamin Hanfstein is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Benjamin Hanfstein has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 20 papers in Genetics and 12 papers in Rheumatology. Recurrent topics in Benjamin Hanfstein's work include Chronic Myeloid Leukemia Treatments (22 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Eosinophilic Disorders and Syndromes (12 papers). Benjamin Hanfstein is often cited by papers focused on Chronic Myeloid Leukemia Treatments (22 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Eosinophilic Disorders and Syndromes (12 papers). Benjamin Hanfstein collaborates with scholars based in Germany, United States and Switzerland. Benjamin Hanfstein's co-authors include Andreas Hochhaus, Rüdiger Hehlmann, Nicholas C.P. Cross, Sebastian Kreil, Paul La Rosée, Ute Berger, Harald Gschaidmeier, A. Corbin, Claudia Schoch and Brian Druker and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Benjamin Hanfstein

27 papers receiving 1.1k citations

Hit Papers

Molecular and chromosomal mechanisms of resistance to ima... 2002 2026 2010 2018 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
    2002 675 citations Andreas Hochhaus, Sebastian Kreil et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Hanfstein Germany 11 983 784 562 147 139 28 1.1k
Manuel Ayala Mexico 4 1.0k 1.0× 854 1.1× 548 1.0× 103 0.7× 172 1.2× 10 1.2k
Sabrina Colarossi Italy 9 733 0.7× 606 0.8× 537 1.0× 71 0.5× 61 0.4× 21 1.1k
Franck E. Nicolini France 19 1.5k 1.5× 1.2k 1.6× 697 1.2× 195 1.3× 253 1.8× 64 1.7k
Melissa Holtz United States 9 904 0.9× 610 0.8× 405 0.7× 318 2.2× 207 1.5× 11 1.1k
Simona Luatti Italy 12 703 0.7× 622 0.8× 444 0.8× 76 0.5× 56 0.4× 24 788
Teresa Davies United Kingdom 7 482 0.5× 340 0.4× 149 0.3× 210 1.4× 90 0.6× 9 719
Wendy T Parker Australia 10 390 0.4× 330 0.4× 170 0.3× 118 0.8× 78 0.6× 22 537
Tanja Lahaye Germany 12 1.2k 1.3× 1.0k 1.3× 762 1.4× 174 1.2× 141 1.0× 22 1.4k
Abdulraheem Yacoub United States 15 467 0.5× 551 0.7× 212 0.4× 366 2.5× 206 1.5× 122 917
Matthew S. Zabriskie United States 9 416 0.4× 301 0.4× 113 0.2× 307 2.1× 170 1.2× 24 720

Countries citing papers authored by Benjamin Hanfstein

Since Specialization
Citations

This map shows the geographic impact of Benjamin Hanfstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Hanfstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Hanfstein more than expected).

Fields of papers citing papers by Benjamin Hanfstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Hanfstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Hanfstein. The network helps show where Benjamin Hanfstein may publish in the future.

Co-authorship network of co-authors of Benjamin Hanfstein

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Hanfstein. A scholar is included among the top collaborators of Benjamin Hanfstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Hanfstein. Benjamin Hanfstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hanfstein, Benjamin, Martin C. Müller, & Andreas Hochhaus. (2015). Response-related predictors of survival in CML. Annals of Hematology. 94(S2). 227–239. 18 indexed citations
2.
Nowak, Daniel, Verena Nowak, Benjamin Hanfstein, et al.. (2015). A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia. Leukemia Research. 39(11). 1172–1177. 6 indexed citations
3.
Agrawal, Mridul, Benjamin Hanfstein, Philipp Erben, et al.. (2014). MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure. Leukemia. 28(7). 1478–1485. 15 indexed citations
4.
Lauseker, Michael, Benjamin Hanfstein, Claudia Haferlach, et al.. (2014). Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. Journal of Cancer Research and Clinical Oncology. 140(11). 1965–1969. 19 indexed citations
5.
Schwaab, Juliana, Christian Dietz, Benjamin Hanfstein, et al.. (2014). Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML). Journal of Cancer Research and Clinical Oncology. 140(3). 411–417. 3 indexed citations
6.
Nolte, Florian, Daniel Nowak, Verena Nowak, et al.. (2014). Prognostic importance of expression of the Wilms’ tumor 1 gene in newly diagnosed acute promyelocytic leukemia. Leukemia & lymphoma. 56(8). 2289–2295. 8 indexed citations
7.
8.
Nowak, Daniel, Verena Nowak, Benjamin Hanfstein, et al.. (2012). High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia. Annals of Hematology. 92(4). 443–449. 6 indexed citations
9.
Nolte, Florian, Mark Reinwald, Daniel Nowak, et al.. (2012). In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival. Leukemia Research. 37(4). 378–382. 10 indexed citations
10.
Härtel, Nicolai, Thomas Klag, Benjamin Hanfstein, et al.. (2011). Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. Journal of Cancer Research and Clinical Oncology. 138(2). 203–212. 5 indexed citations
11.
Lengfelder, Eva, Benjamin Hanfstein, Claudia Haferlach, et al.. (2011). Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group. Blood. 118(21). 425–425. 2 indexed citations
12.
Erben, Philipp, Philipp Ströbel, Karoline Horisberger, et al.. (2010). KRAS and BRAF Mutations and PTEN Expression Do Not Predict Efficacy of Cetuximab-Based Chemoradiotherapy in Locally Advanced Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics. 81(4). 1032–1038. 39 indexed citations
13.
Müller, Martin C., Andreas Hochhaus, Michael Lauseker, et al.. (2010). Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV. Blood. 116(21). 669–669. 5 indexed citations
14.
Hanfstein, Benjamin, Martin C. Müller, Sebastian Kreil, et al.. (2010). Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica. 96(3). 360–366. 36 indexed citations
15.
Hochhaus, Andreas, Martin C. Müller, Jerald P. Radich, et al.. (2009). Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia. 23(9). 1628–1633. 29 indexed citations
16.
Müller, Martin, Nicholas C.P. Cross, Philipp Erben, et al.. (2009). Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 23(11). 1957–1963. 139 indexed citations
17.
Ernst, Thomas, Philipp Erben, Benjamin Hanfstein, et al.. (2008). ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 93(9). 1389–1393. 41 indexed citations
18.
Klag, Thomas, Benjamin Hanfstein, Martin Mueller, et al.. (2007). Imatinib Treatment Induces Growth and Survival Promoting MAPK1/2 in Hematopoietic Cell Lines Expressing BCR-ABLT315I.. Blood. 110(11). 3460–3460.
19.
Sacha, Tomasz, Andreas Hochhaus, Benjamin Hanfstein, et al.. (2003). ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leukemia Research. 27(12). 1163–1166. 16 indexed citations
20.
Hochhaus, Andreas, Sebastian Kreil, A. Corbin, et al.. (2002). Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16(11). 2190–2196. 675 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuel Ayala Breakdown of academic impact, for papers by Sabrina Colarossi Breakdown of academic impact, for papers by Franck E. Nicolini Breakdown of academic impact, for papers by Melissa Holtz Breakdown of academic impact, for papers by Simona Luatti Breakdown of academic impact, for papers by Teresa Davies Breakdown of academic impact, for papers by Wendy T Parker Breakdown of academic impact, for papers by Tanja Lahaye Breakdown of academic impact, for papers by Abdulraheem Yacoub Breakdown of academic impact, for papers by Matthew S. Zabriskie
Rankless by CCL
2026